India Generic Drugs: "Antitrust Unredacted"
New information in the government's investigation into antitrust violations by generic drug companies continues to surface. An unredacted version...
160 Views
India Generic Drugs: Antitrust Suit Could Cost Billions
This Insight builds on our previous Insight, India Generic Drugs: US Antitrust Inquiry Widens by discussing estimated potential liabilities and...
776 Views
India Generic Drugs: US Antitrust Inquiry Widens
The US government's antitrust investigation of the generic drug industry has been quiet for more than a year and has resurfaced with a...
547 Views
Para IV Winners and Losers - September 2018
This month’s Para IV developments suggest that there is likely to be benefit to Teva Pharmaceutical Sp Adr (TEVA US) on Vesicare, Soolantra and...
448 Views
Para IV Winners & Losers - May 2018
This month’s Para IV developments suggest that there is likely to be benefit to Amneal Pharmaceuticals Inc (AMRX US) on Lialda, BioQ pharma for...
114 Views